Analysts Set Nkarta, Inc. (NASDAQ:NKTX) Target Price at $13.25

Shares of Nkarta, Inc. (NASDAQ:NKTX) have been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $13.25.

NKTX has been the topic of several research analyst reports. Wall Street Zen raised Nkarta from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Nkarta in a report on Monday, December 15th. Finally, Stifel Nicolaus reduced their price target on shares of Nkarta from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, November 11th.

Institutional Trading of Nkarta

A number of institutional investors have recently added to or reduced their stakes in NKTX. Alyeska Investment Group L.P. raised its position in Nkarta by 54.7% in the first quarter. Alyeska Investment Group L.P. now owns 2,064,956 shares of the company’s stock valued at $3,800,000 after purchasing an additional 730,260 shares during the period. Monaco Asset Management SAM grew its stake in shares of Nkarta by 24.5% in the third quarter. Monaco Asset Management SAM now owns 1,970,910 shares of the company’s stock valued at $4,080,000 after buying an additional 387,538 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Nkarta by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,208,378 shares of the company’s stock valued at $2,006,000 after buying an additional 10,065 shares during the period. AWM Investment Company Inc. raised its holdings in shares of Nkarta by 150.0% during the 1st quarter. AWM Investment Company Inc. now owns 1,000,000 shares of the company’s stock valued at $1,840,000 after buying an additional 600,000 shares during the period. Finally, Millennium Management LLC acquired a new position in Nkarta during the 3rd quarter worth approximately $1,549,000. 80.54% of the stock is owned by hedge funds and other institutional investors.

Nkarta Stock Up 0.5%

Shares of NASDAQ NKTX opened at $1.85 on Friday. The stock has a market capitalization of $131.41 million, a PE ratio of -1.34 and a beta of 0.80. The firm has a fifty day moving average of $1.92 and a 200-day moving average of $2.00. Nkarta has a 52-week low of $1.31 and a 52-week high of $2.74.

Nkarta (NASDAQ:NKTX) last issued its earnings results on Monday, November 10th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.03. Equities research analysts expect that Nkarta will post -1.7 EPS for the current fiscal year.

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.